34 results
8-K
EX-3.2
THRX
Theseus Pharmaceuticals Inc
14 Feb 24
Completion of Acquisition or Disposition of Assets
10:44am
Operating Officer shall have general responsibility for the management and control of the operations of the Corporation. The Chief Operating Officer shall
SC TO-T/A
EX-99
Concentra Merger Sub II, Inc.
14 Feb 24
Third party tender offer statement (amended)
10:35am
of the Company Common Stock held by such Holders as of immediately prior to the Effective Time. The Rights Agent will have no responsibility whatsoever directly … have no responsibility or liability for any diminution of funds that may result from any deposit or investment made by Rights Agent in accordance
SC TO-T/A
EX-99
THRX
Theseus Pharmaceuticals Inc
30 Jan 24
Third party tender offer statement (amended)
8:23am
and TCM are considered co-offerors in the Offer. As co-offerors, TCP and TCM accept joint responsibility for the accuracy of the disclosures made … -offerors, TCP and TCM accept joint responsibility for the accuracy of the disclosures made in this Offer to Purchase.
The following are some questions
SC 14D9
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Tender offer solicitation
9:47am
verification or any responsibility therefor, the accuracy and completeness of the financial, legal, regulatory, tax, accounting and other information supplied … on, and the information made available to Leerink Partners as of, the date of its written opinion, and Leerink Partners does not have any obligation or responsibility
SC TO-T
EX-99
THRX
Theseus Pharmaceuticals Inc
10 Jan 24
Third party tender offer statement
8:51am
and the general partner of TCP. Accordingly, TCP and TCM are considered co-offerors in the Offer. As co-offerors, TCP and TCM accept joint responsibility … responsibility for the accuracy of the disclosures made in this Offer to Purchase.
The following are some questions you, as a stockholder of Theseus, may have
SC TO-T
EX-99
691azcyroi8 0ixr
10 Jan 24
Third party tender offer statement
8:51am
8-K
EX-2.1
zirt e52s
22 Dec 23
Entry into a Material Definitive Agreement
6:36am
8-K
EX-10.2
2a5qm2y4s vvssw
13 Nov 23
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
4:06pm
PRE 14A
7owyb 06u3
14 Apr 23
Preliminary proxy
9:00am
S-3
EX-1.2
3ez 80m2ycl
3 Nov 22
Shelf registration
9:06am
S-3
EX-4.6
kkwfe pe2r65mi86wj9
3 Nov 22
Shelf registration
9:06am
S-3
jspnt
3 Nov 22
Shelf registration
9:06am
S-3
EX-4.5
zpm8 2o032pp7
3 Nov 22
Shelf registration
9:06am
8-K
EX-99.1
bxqsyo390m amvo3hk
12 May 22
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2022 Financial Results
7:15am
DEF 14A
4ltdoqr44l4j
25 Apr 22
Definitive proxy
4:30pm
10-K
jvexc
10 Mar 22
Annual report
7:23am
10-Q
po8gd
15 Nov 21
Quarterly report
7:36am
424B4
papqt7d5b
7 Oct 21
Prospectus supplement with pricing info
5:03pm